RCM
ASMB icon

RA Capital Management’s Assembly Biosciences ASMB Stock Holding History

RA Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.3M Hold
1,020,410
– – 0.3% 48
2025
Q4 		$34.7M Hold
1,020,410
– – 0.36% 43
2025
Q3 		$26.1M Buy
+1,020,410
New +$22.4M 0.32% 39

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RA Capital Management's ASMB Position: Q1 2026 in Review

RA Capital Management held its Assembly Biosciences (ASMB) position steady in Q1 2026 at 1,020,410 shares worth $28.3M. The position accounts for 0.3% of the portfolio, ranked #48.

RA Capital Management first reported a position in ASMB in Q3 2025 and has held it in 3 quarters since. The position peaked at $34.7M in Q4 2025. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • RA Capital Management held 1,020,410 shares of Assembly Biosciences worth $28.3M as of Q1 2026.
  • RA Capital Management left its Assembly Biosciences share count unchanged in Q1 2026.
  • Assembly Biosciences made up 0.3% of RA Capital Management's portfolio in Q1 2026, its #48 holding.
  • RA Capital Management first reported a position in Assembly Biosciences in Q3 2025 and has held it in 3 quarters since.
  • RA Capital Management's Assembly Biosciences position peaked at $34.7M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.